1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Indonesia Pharmaceuticals and Healthcare Report Q4 2016

Indonesia Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 127 pages

Includes 3 FREE quarterly updates


BMI View: Pressure to increase premiums charged for Indonesia's universal healthcare scheme will remain as it struggles with financial stability. Financial subsidies from the government to support the programme will alleviate but not fully address the challenge, due to fiscal constraints. Such shifts to the country's healthcare insurance programme will have influence the opportunities of healthcare providers and drugmakers as it serves as a key driver of patient volume growth and medicine sales, respectively.

Headline Expenditure Projections
- Pharmaceuticals: IDR77.6trn (USD5.8bn) in 2015 to IDR85.6trn (USD6.3bn) in 2016; +10.2% growth in local currency terms and +9.7% in US dollar terms.
- Healthcare: IDR330trn (USD24.6bn) in 2015 to IDR367trn (USD27bn) in 2016; +11.2% growth in local currency terms and +10.7% in US dollar terms. Forecast revised upwards after incorporating a significant increase in the government healthcare budget. Currency fluctuations reinforced the change in US dollar terms.

Table Of Contents

Indonesia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Indonesia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Indonesia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Indonesia 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Indonesia 2014-2020) 32
Industry Risk/Reward Index 33
Asia Pacific Risk/Reward Index - Q4 2016 33
Indonesia Risk/Reward Index 40
Rewards 40
Risks 40
Regulatory Review 42
Intellectual Property Issues 46
Pricing Regime 50
Reimbursement Regime 51
Industry Trends And Developments 52
Market Overview 52
Table: UN Millennium Development Goals For Indonesia 53
Healthcare Sector 54
Table: Healthcare Resources (Indonesia 2010-2015) 57
Table: Healthcare Personnel (Indonesia 2010-2015) 57
Table: Healthcare Activity (Indonesia 2010-2015) 58
Research and Development 58
Clinical Trials 59
Epidemiology 60
Table: Estimated Number Of New Cases Of Cancer In Indonesia 62
Competitive Landscape 65
Research-Based Industry 65
Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions 66
Table: Multinational Market Activity 67
Generic Drugmakers 68
Pharmaceutical Wholesale 69
Pharmaceutical Retail 70
Company Profile 73
Bayer 73
Darya-Varia Group 76
GlaxoSmithKline 79
Indopharma 82
Kimia Farma 85
Merck and Co 89
Merck Group 92
Novartis 95
Pfizer 98
PT Biofarma 101
PT Kalbe Farma 105
Sanofi 110
Soho Group 113
Demographic Forecast 116
Demographic Outlook 116
Table: Population Headline Indicators (Indonesia 1990-2025) 117
Table: Key Population Ratios (Indonesia 1990-2025) 117
Table: Urban/Rural Population and Life Expectancy (Indonesia 1990-2025) 118
Table: Population By Age Group (Indonesia 1990-2025) 118
Table: Population By Age Group % (Indonesia 1990-2025) 119
Glossary 121
Methodology 123
Pharmaceutical Expenditure Forecast Model 123
Healthcare Expenditure Forecast Model 123
Notes On Methodology 124
Risk/Reward Index Methodology 125
Index Overview 126
Table: Pharmaceutical Risk/Reward Index Indicators 126
Indicator Weightings 127

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.